Business Context and Reporting Period
This summary covers the Form 10-Q for Aileron Therapeutics, Inc. (ALRN) for the quarterly period ended September 30, 2024. Aileron is a clinical-stage biopharmaceutical company focused on developing therapies for orphan pulmonary and fibrosis indications. Following the acquisition of Lung Therapeutics, Inc. in October 2023, the company's primary pipeline consists of LTI-03 (for Idiopathic Pulmonary Fibrosis) and LTI-01 (for loculated pleural effusion). In June 2024, the company temporarily delayed clinical development of LTI-01 to focus resources on LTI-03 and raise additional capital. The company operates virtually following the expiration of its Austin, Texas office lease in March 2024.
Key Financial Metrics
| Metric | Q3 2024 (3 Months) | Q3 2023 (3 Months) | YTD 2024 (9 Months) | YTD 2023 (9 Months) |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Loss | $(5.85) million | $(1.83) million | $(21.90) million | $(8.39) million |
| Net Loss Per Share (Basic/Diluted) | $(0.27) | $(0.40) | $(1.31) | $(1.85) |
| Operating Expenses | $6.07 million | $1.98 million | $22.32 million | $8.99 million |
| Cash and Cash Equivalents (Sept 30, 2024) | $17.65 million | |||
| Accumulated Deficit (Sept 30, 2024) | $(310.42) million | |||
| Net Cash Used in Operating Activities (YTD) | $(17.48) million | $(9.42) million |
Material Changes vs. Prior Period
- Expense Surge: Operating expenses increased significantly compared to the prior year periods. This is primarily attributable to the integration of Lung Therapeutics' clinical programs (LTI-03 and LTI-01) following the October 2023 acquisition.
- R&D Expenses: Increased from $22,000 in Q3 2023 to $3.72 million in Q3 2024. YTD R&D rose from $2.02 million to $10.93 million.
- Manufacturing Write-offs: The company incurred $0.8 million in Q3 and $3.2 million YTD in manufacturing write-offs due to the temporary delay of LTI-01 development and expiration of clinical materials.
- Financing Activity: In May 2024, the company completed an underwritten follow-on public offering, raising approximately $17.7 million in net proceeds. This contrasts with no financing proceeds in the same period in 2023.
- Capital Structure: Significant conversion of Series X non-voting convertible preferred stock into common stock occurred in Q1 and Q2 2024, increasing the weighted average shares outstanding from ~4.5 million in 2023 to ~16.7 million YTD 2024.
Outlook, Risks, and Management Commentary
- Going Concern Warning: Management explicitly states that cash and cash equivalents of $17.65 million as of September 30, 2024, are not sufficient to fund operations for at least twelve months from the filing date. This raises substantial doubt about the company's ability to continue as a going concern. Management estimates funds will last into June 2025.
- Clinical Progress:
- LTI-03: Positive topline data from Cohort 2 of the Phase 1b trial was announced in November 2024, showing statistically significant decreases in multiple profibrotic biomarkers. Planning for a Phase 2 trial is underway.
- LTI-01: Development is temporarily delayed pending additional funding.
- Subsequent Event: On October 31, 2024, the company entered an exclusive option agreement with Advancium Health Network for the sale of ALRN-6924 (retinoblastoma), receiving a $100,000 non-refundable fee.
- Internal Controls: The company identified material weaknesses in internal controls over financial reporting related to accounting personnel, segregation of duties, and acquisition accounting. Remediation efforts are ongoing but not yet complete.
- Capital Needs: The company expects to require substantial additional funding through equity or debt financings, collaborations, or licensing arrangements to continue operations and advance clinical trials.
Investor Verification Checklist
- Liquidity Runway: Verify the specific timeline for cash exhaustion (estimated June 2025) and the status of any new financing discussions.
- Warrant Call Provisions: Review the terms of the May 2024 offering warrants, which are callable by the company if the stock price exceeds the exercise price ($4.68) following the Phase 1b topline results announcement.
- Material Weaknesses: Monitor the progress of remediation for internal control weaknesses, particularly regarding the accounting for the Lung Acquisition and segregation of duties.
- Phase 2 Trial Funding: Assess the capital requirements for the planned Phase 2 trial of LTI-03 and the likelihood of securing funding without significant dilution.
- Advancium Option: Track the status of the exclusive option agreement with Advancium for potential future milestone payments.